Breaking News

Financial Report: Teva

February 12, 2016

Specialty Medicines down 6% in the quarter

Teva

4Q Revenues: $4.9 billion (-6%)

4Q Earnings: $498 million (-28%)

FY Revenues: $19.7 billion (-3%)

FY Earnings: $1.6 billion (-48%)

Comments: Specialty Medicines revenue was $2.1 billion in the quarter, down 6%, primarily due to lower sales of Copaxone and Azilect, which were partially offset by higher revenues of respiratory products. Specialty Medicines accounted for 44% of total revenues in the quarter. Generic Medicines revenue was $2.3 billion in the quarter, down 9%. R&D expenses were $395 million in the quarter, up 14%. Exchange rate fluctuations reduced revenues by $259 million in the quarter, and $1.3 billion for the year.
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer